FDA Warning Letter: SCA Pharmaceuticals cited for aseptic processing and contamination-control deficiencies

What happened

FDA states that its October 20–30, 2025, inspection of SCA Pharmaceuticals’ Little Rock outsourcing facility found serious deficiencies in production of drugs intended or expected to be sterile. Investigators cited inadequate certification and dynamic airflow visualization of ISO 5 areas, airflow and HEPA-supplied positive-pressure concerns, poor aseptic practices, deficient material disinfection, and environmental monitoring that was not representative of production conditions. FDA also found inadequate evaluation of microbial contamination in ISO 5 areas and insufficient investigations, CAPA, and batch-impact assessments. Component and visual inspection controls did not adequately identify, classify, investigate, trend, or address particles and foreign material between syringe stopper ribs. Laboratory controls and Quality Unit procedures were cited as inadequate. Production videos used in investigations were overwritten after approximately a redacted period, with only still images retained. FDA found some responses deficient and could not fully evaluate others because supporting documentation was inadequate, and recommended a comprehensive aseptic operations assessment assisted by a qualified sterile-manufacturing consultant.

Why it matters

These findings may weaken sterility assurance because airflow disruption, poor first-air protection, inadequate disinfection, and unrepresentative monitoring can reduce confidence that aseptic operations remain controlled. Incomplete evaluation of microbial excursions and particulate defects may leave contamination risks insufficiently assessed for released batches. Overwritten investigation videos may limit reconstruction of events and verification of root causes and corrective actions. FDA’s concerns about airflow studies and supporting documentation also indicate that the effectiveness and scope of remediation were not fully demonstrated.

Key topics: Deficient ISO 5 airflow studies and aseptic operator practices, Inadequate microbial excursion investigations and batch-impact assessments, Insufficient particulate controls and retention of investigation videos

Source: U.S. Food and Drug Administration (FDA)